GLP-1 C-terminal structures affect its blood glucose lowering-function

Journal of Peptide Science

Volumn 14, Issue 7, 2008, Pages 777-785

  Li, Yuan ^a   Shi, Changhong ^b   Lv, Qiujun ^c   Zhang, Huming ^d   Li, Biehu ^a   Bian, Guangxing ^c   Huang, Qingsheng ^a   Zhang, Weihua ^a   Xue, Xiaoping ^a   Ren, Xin ^e   Gao, Hua ^a   Sun, Chunyi ^a   Wang, Juan ^a   Zhang, Mingjie ^a  

^a Dalian DN Bio Engineering Co Ltd   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c Institute of Radiology   (China)

^d Xian Lianmei Biotech Co Ltd   (China)

^e DALIAN UNIVERSITY   (China)

Author keywords

Apoptosis; Diabetes; GLP 1; Islet

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 [7-27]; GLUCAGON LIKE PEPTIDE 1 [7-30]; GLUCAGON LIKE PEPTIDE 1 [7-32]; GLUCAGON LIKE PEPTIDE 1 [7-37]; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD GLUCOSE MONITORING; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; FEMALE; GENE DELETION; GLUCOSE BLOOD LEVEL; IN VIVO STUDY; INSULIN RELEASE; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; STRUCTURE ACTIVITY RELATION;

ANIMAL FEED; ANIMALS; APOPTOSIS; BLOOD GLUCOSE; CELL PROLIFERATION; DIABETES MELLITUS, TYPE 2; FATS; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; ISLETS OF LANGERHANS; MALE; MICE; PEPTIDE FRAGMENTS; RATS; STREPTOZOCIN;

RATTUS;

EID: 48249109559     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.997     Document Type: Article

References (24)

1. Mojsov S, Heinrich G, Wilson IB, Ravazzola M, Orci L, Habener JF. Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J. Biol. Chem. 1986; 261: 11880-11889.
2. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987; 2: 1300-1304.
3. Bell GI, Santerre RF, Mullenbach GT. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 1983; 302: 716-718.
4. Goke R, Conlon JM. Receptors for glucagon-like peptide-1(7-36) amide on rat insulinoma-derived cells. J. Endocrinol. 1988; 116: 357-362.
5. D'Alessio DA, Sandoval DA, Seeley RJ. New ways in which GLP-1 can regulate glucose homeostasis. J. Clin. Invest. 2005; 115: 3406-3408.
6. Vahl TP, Paty BW, Fuller BD, Prigeon RL, D'Alessio DA. Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J. Clin. Endocrinol. Metab. 2003; 88: 1772-1779.
7. Weir GC, Mojsov S, Hendrick GK, Habener JF. Glucagonlike peptide I (7-37) actions on endocrine pancreas. Diabetes 1989; 38: 338-342.
8. Orskov C, Wettergren A, Holst JJ. Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 1993; 42: 658-661.
9. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 1995; 80: 952-957.
10. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 1993; 214: 829-835.
11. Nauck MA, Hompesch M, Filipczak R, Le TD, Zdravkovic M, Gumprecht J. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 2006; 114: 417-423.
12. Bregenholt S, Moldrup A, Blume N, Karlsen AE, Nissen Friedrichsen B, Tornhave D, Knudsen LB. Petersen JS. The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochem. Biophys. Res. Commun. 2005; 330: 577-584.
13. Kim JG, Baggio LL, Bridon DP, Castaigne JP, Robitaille MF, Jette L, Benquet C, Drucker DJ. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes 2003; 52: 751-759.
14. Beinborn M, Worrall CI, McBride EW, Kopin AS. A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness. Regul. Pept. 2005; 130: 1-6.
15. Doyle ME, Theodorakis MJ, Holloway HW, Bernier M, Greig NH, Egan JM. The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity. Regul. Pept. 2003; 114: 153-158.
16. Suzuki S, Kawai K, Ohashi S, Mukai H, Yamashita K. Comparison of the effects of various C-terminal and N-terminal fragment peptides of glucagon-like peptide-1 on insulin and glucagon release from the isolated perfused rat pancreas. Endocrinology 1989; 125: 3109-3114.
17. German MS, Moss LG, Rutter WJ. Regulation of insulin gene expression by glucose and calcium in transfected primary islet cultures. J. Biol. Chem. 1990; 265: 22063-22066.
18. Drucker D. Glucagon-like peptides. Diabetes 1998; 47: 159-169.
19. Holst JJ. Glucagon-like peptide 1 (GLP-1): an intestinal hormone, signalling nutritional abundance, with an unusual therapeutic potential. Trends Endocrinol. Metab. 1999; 10: 229-235.
20. Drucker DJ. Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology 2003; 144: 5145-5148.
21. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J. Biol. Chem. 2003; 278: 471-478.
22. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J. Biol. Chem. 1992; 267: 7402-7405.
23. Egan JM, Clocquet AR, Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J. Clin. Endocrinol. Metab. 2002; 87: 1282-1290.
24. Gefel D, Hendrick GK, Mojsov S, Habener J, Weir GC. Glucagon-like peptide-I analogs: effects on insulin secretion and adenosine 3′,5′-monophosphate formation. Endocrinology 1990; 126: 2164-2168.